Feng Xuan

10PUBLICATIONS
1CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersSocio-economic developmentMolecular targetsMajor global burdens of disease
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jul 27, 2026
Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China.

|Apr 09, 2026
Benmelstobart Plus Anlotinib Is Unlikely to Be Cost-Effective for Advanced Renal Cell Carcinoma: An Integrated Disease Burden and Cost-Effectiveness Analysis.

Haiyan Xu, Liejiong Wang, Ying Lou

|Feb 25, 2026
Temporal Trends in Mortality of Female Cancers Among Women and the Impact of COVID-19 in Low- and Middle-Income Countries, 1990-2023: An Age-Period-Cohort Analysis from the Global Burden of Disease Study 2023.

Haolin Zhong, Shengjian Yu, Yitong Huang

|Nov 06, 2025
Global burden, health inequalities and improvement gap of head and neck cancers in middle-aged and older adults from 1990 to 2021.

Minxia Yang, Feng Xuan, Xiaofeng Ma

|Sep 19, 2025
Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).

Minxia Yang, Di Qiu, Minguang Huang

|Aug 05, 2025
Trends and inequalities in gastrointestinal cancer care quality from 1990 to 2021: A population-based analysis of the Global Burden of Disease Study 2021.

Minxia Yang, Guodong Wang, Ying Lou

Pageof 2

Frequent Collaborators

1 joint publications

Zhaoqi Qiu